Risk minimisation materials for Medabon Combipack (mifepristone 200 mg tablet and misoprostol 4 x 0.2 mg vaginal tablets) combination therapy for medical abortion

A delivery guideline discusses screening, prescribing, administering and follow-up, and there is a separate guideline for those who may see women presenting for emergency care following treatment, discussing the serious complications. A patient card is also available.

SPS commentary:

Medabon is indicated for medical termination of developing intra-uterine pregnancy of up to 63 days of amenorrhoea. 200mg of mifepristone (one tablet) is taken in a single oral dose, followed 36 to 48 hours later by the administration of misoprostol 800 micrograms (i.e. 4 vaginal tablets of 0.2mg each) vaginally in a single dose. Misoprostol vaginal tablets can be administered by a health care provider or by the woman herself.

Serious complications of treatment include heavy or prolonged bleeding and pelvic infection; providers should also be alert for undiagnosed ectopic pregnancy.


electronic Medicines compendium

Resource links:

Medical and Service Delivery Guideline

Medical Guidelines for Providers of Emergency Care

Patient card